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Abstract Disease progression modelling can provide information about the time
course and outcome of pharmacological intervention on the disease. The basic PK/
PD principles of proliferative and circular systems within the context of modelling
disease progression and the effect of treatment thereupon are illustrated with the goal
to better understand/predict eventual clinical outcome. Circular/proliferative systems
can be very complex. To facilitate the understanding of how a dosing regimen can be
deﬁned in such systems we have shown the derivation of a system parameter named
the Reproduction Minimum Inhibitory Concentration (RMIC) which represents the
critical concentration at which the system switches from growth to extinction. The
RMIC depends on two parameters (RMIC = (R0 - 1) 9 IC50): the basic repro-
ductive ratio (R0) a fundamental parameter of the circular/proliferative system that
represents the number of offspring produced by one replicating species during its
lifespan, and the IC50, the potency of the drug to inhibit the proliferation of the
system. The RMIC is constant for a given system and a given drug and represents the
lowest concentration that needs to be achieved for eradication of the system. When
exposure is higher than the RMIC, success can be expected in the long term. Time
varying inhibition of replicating species proliferation is a natural consequence of the
time varying inhibitor drug concentrations and when combined with the dynamics of
the circular/proliferative system makes it difﬁcult to predict the eventual outcome.
Time varying inhibition of proliferative/circular systems can be handled by calcu-
lating the equivalent effective constant concentration (ECC), the constant plasma
concentration that would give rise to the average inhibition at steady state. When
ECC is higher than the RMIC, eradication of the system can be expected. In addition,
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DOI 10.1007/s10928-010-9151-7it is shown that scenarios that have the same steady state ECC whatever the dose,
dosage schedule or PK parameters have also the same average R0 in the presence of
the inhibitor (i.e. R0-INH) and therefore lead to the same outcome. This allows pre-
dicting equivalent active doses and dosing schedules in circular and proliferative
systems when the IC50 and pharmacokinetic characteristics of the drugs are known.
The results from the simulations performed demonstrate that, for a given system
(deﬁned by its RMIC), treatment success depends mainly on the pharmacokinetic
characteristics of the drug and the dosing schedule.
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Introduction
The role of modelling in the science of clinical pharmacology is undisputed [1, 2].
In parallel with the increasingly widespread application of the art of modelling, the
models themselves have become more complex; physiologically based pharmaco-
kinetic (PBPK) models in pharmacokinetics (PK) [3] and more mechanistic
pharmacokinetic/pharmacodynamic (PK/PD) models [4–8] are increasingly com-
mon. In some sense there is the impression that mechanism based PK/PD and
disease modelling is rapidly moving from an empirical approach [9] towards the
bottom-up approach usually associated with systems biology [10].
Disease progression modelling in combination with modelling the inﬂuence of
drug action on the parameters of the disease progression model can provide
information about the time course and outcome of pharmacological intervention on
the disease. Disease progression modelling has been reviewed by Chan and Holford
[11] and Danhof et al. [8]. The incorporation of circular/proliferative systems within
the ﬁeld of disease modelling offers further potential to advance the mechanistic
development and application of disease models. One of the most advanced circular/
proliferative system is the predator/prey example, independently introduced by
Lotka in 1925 [12] and Volterra in 1926 [13] and adapted for viral dynamics by
Nowak and Bonhoeffer [14–17]. In the predator/prey system, the predators multiply
when there are many prey, but, the predators eventually outgrow their food supply
and consequently decline in number. As the predator population declines, the prey
population increases again. These dynamic interactions continue in cycles of growth
and decline. Intuitively, it can be seen that proliferative systems such as infectious
diseases (viral, bacterial and fungal) and cancer share at least the same circular
aspect in which the organisms of each generation are produced from identical
organisms of the previous generation. Another therapeutic area where models for
circular/proliferative systems could be applied is immunology, speciﬁcally to
describe allergy and inﬂammation.
A fundamental parameter of the circular/proliferative system is the basic
reproductive ratio (R0). This parameter is a system speciﬁc parameter and is
independent of the drug being used to treat the illness. Simply put it is the number of
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123offspring produced by one replicating species during its lifespan. The R0 is a
concept that has been used within the epidemiological ﬁeld for some time and has
been reviewed by Heffernan et al. [18].
Combination of circular and proliferative systems with PK/PD principles leads to
speciﬁc system behaviour that can have therapeutic implications. This article
focuses on introducing the basic PK/PD (concentration/effect) principles of
proliferative and circular systems within the context of modelling disease
progression and the effect of treatment thereupon. The importance of the ability
to deﬁne the R0 for the system will be illustrated, with respect to identifying if
treatment intervention can be successful or not. Further, which pharmacokinetic
parameter is most appropriate to use when comparing different doses and dosage
schedules within circular/proliferative systems will be examined. Furthermore, how
short term observations (studies) can be used to predict long term clinical outcome
will be demonstrated. In the spirit of generality a simple circular/proliferative
system will be used to illustrate the principles presented. A more complex viral
infection model will also be used to highlight the same principles.
The ultimate aim of this body of work is to show generally how the circular/
proliferative models can be linked to both pharmacodynamic disease models and the
pharmacokinetics of the drug under study, to better understand/predict dosing
regimens and eventual clinical outcome.
Theory
In this section two circular/proliferative systems will be presented in order to
introduce the R0 concept. The ﬁrst circular/proliferative system is a simple one and
is described to present the theoretical concepts. The second circular/proliferative
system is more complex but has greater practical relevance.
A simple circular/proliferative system model
Consider the simple circular/proliferative system model illustrated in Fig. 1. The
system is simple in that there is no interaction of B with potential partners in the
system (e.g. bacteria can grow by themselves, they do not need host cells to
reproduce). In Fig. 1, km is the production rate of new B and kd is the death rate of
B. If km[kd then the system will grow. If km\kd, the system will go to
extinction. If km equals kd then the system will just survive.
The R0 is deﬁned as the ratio of km to kd and is the number of new Bs produced
by one B during its lifespan. By simple extension, if R0 is greater than 1, the system
will grow. If R0 is less than 1, the system will go to extinction. If R0 equals 1 then
the system will just survive.
Consider now the introduction of an inhibitor of km into the system, also
illustrated in Fig. 1. The degree of inhibition caused by the inhibitor (INH) can be
expressed as shown in Eq. 1 [19].
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IC
IC50 þ IC ðÞ
ð1Þ
where IC is the plasma concentration of the inhibitor and IC50 is the plasma con-
centration of inhibitor that results in 50% inhibition. The rate of change of B with
respect to time t, in the presence of inhibitor, is illustrated in Eq. 2.
dB
dt
¼ 1   INH ðÞ   km   B   kd   B ð2Þ
The basic reproductive ratio in the presence of the inhibitor (R0-INH) can be
obtained from
R0 INH ¼
1   INH ðÞ   km
kd
¼ 1   INH ðÞ   R0 ð3Þ
Again, if R0-INH is greater than 1, the system will continue to grow; if R0-INH is
less than 1, the system will die and if R0-INH equals 1, then the system will just
survive.
Proliferative systems in the presence of an inhibitor are characterized by the
Reproduction Minimum Inhibitory Concentration (RMIC). When inhibition is such
that the system just survives, then
R0 INH ¼ 1 ¼ 1   INH ðÞ   R0 ð4Þ
Therefore,
1 ¼ 1  
IC
IC50 þ IC

  R0 ð5Þ
which rearranges to
IC ¼ R0   1 ðÞ   IC50 ð6Þ
Since Eq. 6 was derived under circumstances where the system just survives,
then, in this case, IC is equivalent to RMIC. Therefore
RMIC ¼ R0   1 ðÞ   IC50 ð7Þ
In Eq. 7 R0 is a system speciﬁc parameter and IC50 is a drug (inhibitor) speciﬁc
parameter.
kd
km
Inhibitor
INH
B
Inhibitor Fig. 1 A simple circular/
proliferative system model with
inhibitor present that causes
inhibition (INH)
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The simple system deﬁned above can now be extended to the more complex viral
dynamic model illustrated in Fig. 2 and used in HIV [17]. The system is more
complex since the virus (B in the simple model) now needs to interact with target
cells in order to reproduce. The model originally included ﬁve different types of
cells (Fig. 2): target CD4 cells (T), actively infected cells (A), latently infected cells
(L) which eventually can be reactivated to actively infected cells, persistently
infected cells (P) with a very long half-life (C1,000 days), defectively infected cells
(D), as well as the virus particles (V). However, in the present treatise the
persistently and defectively infected cells have been removed from the model
because they do not signiﬁcantly contribute to the viral load at equilibrium or at
initiation of antiviral treatment.
The interaction between the target cells and the virus is described by differential
equations in this mathematical model:
Target cell activated cells ðÞ :
dT
dt
¼ b   d1   T  ð 1   INHÞ i   V   T ð8Þ
Actively infected cells short-lived ðÞ :
dA
dt
¼ f1  ð 1   INHÞ i   V   T   d2   A þ a   L
ð9Þ
Activated Target cell    +    Virus Actively infected cell
Latently infected cell
Persistently infected cell
Defectively infected cell
Virus production
d1 d2 c
d3
a
p
† † †
†
†
†
b f1
f2
INH i
Virus production
† †
†
f1 INH i
Fig. 2 The viral dynamic model based on the predator–prey system described by Lotka–Volterra.
Pathways in grey are not included in the present analyses. INH indicates the site of drug action. Parameter
deﬁnitions can be found in the text
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dL
dt
¼ f2  ð 1   INHÞ i   V   T   d3   L   a   L ð10Þ
Infectious virus copies HIV-1 RNA ðÞ :
dV
dt
¼ p   A   c   V ð11Þ
where b is the activation rate constant of healthy target cells (T); d1 the death rate
constant of T cells; i the infection rate constant of T cells; V the number of virus
particles; f1 the fraction of healthy T cells which become short-lived infected T cells
(A); d2 the death rate constant of short-lived infected T cells; f2 (=1 - f1) the
fraction of healthy T cells becoming long-lived infected T cells (L); d3 the death rate
constant of latently infected resting cells; a the reactivation rate constant of latently
infected resting cells; p the viral production rate constant of short-lived infected T
cells; c the death rate constant of virus; and INH is the inhibition of the infection
rate by the drug.
This more complex system is also characterized by a R0. Here the R0 is deﬁned as
the average number of secondary viruses generated by viruses introduced into an
uninfected environment.
R0 ¼
b
d1
  i  
p
c
 
f1
d2
þ
f2   a
d2   d3 þ a ðÞ

ð12Þ
where b
d1 is the number of activated Target cells in the absence of virus, i is the
infection rate,
p
c is the amount of circulating virus per infected cell (at steady state),
and
f1
d2 þ
f2 a
d2  d3þa ðÞ is the factor for living, actively infected cells.
An inhibitory Emax model decreasing the infection rate is usually used to describe
the effect of antiretroviral compounds acting before DNA replication, leading to the
same forms for the R0-INH and RMIC formulae as described above for the simple
model;
R0 INH ¼
b
d1
  1   INH ðÞ   i  
p
c
 
f1
d2
þ
f2   a
d2   d3 þ a ðÞ

¼ 1   INH ðÞ   R0 ð13Þ
RMIC ¼ R0   1 ðÞ   IC50 ð7Þ
Attributes of circular/proliferative systems and pharmacodynamic disease
models
The concepts presented above give rise to the following attributes of circular/
proliferative system models with respect to R0 and RMIC, and for binary outcomes
analysis. The various attributes presented below will be illustrated later by means of
simulation.
R0 and RMIC
1. When the inhibitory concentration equals the RMIC the system is in dynamic
equilibrium; the replicating species neither increase nor decrease in number.
162 J Pharmacokinet Pharmacodyn (2010) 37:157–177
1232. Depending on R0, system survival (i.e. R0-INH = 1) can occur at different levels
of inhibition:
For R0 = 2, RMIC = IC50
For R0 = 10, RMIC = 9*I C 50 = IC90.
3. If in vitro and in vivo R0 are different, in vitro and in vivo RMIC will also be
different.
4. From Eq. 7 it can be seen that the RMIC is a joint distribution of R0 and IC50 in
the population.
Binary outcomes analysis
The treatment is regarded as a success if the system is eradicated and a failure if the
system persists. Consequently,
1. Inhibition of circular/proliferative systems naturally leads to binary outcomes
and logistic analysis so an:
• IC greater than RMIC leads to success (the system is eradicated).
• IC less than RMIC leads to failure (the system continues to grow/survive).
2. The time of failure is a function of the IC/RMIC ratio; for failure (when the
ratio is below 1), the smaller the ratio, the sooner the failure will occur.
3. Mechanistically, logistic regression of binary outcomes such as failure/success
rates as a function of inhibitor exposure (IC) is an expression of the RMIC
distribution across the population.
The link between pharmacokinetics and the circular/proliferative
and pharmacodynamic disease models
After drug administration, plasma concentration varies as a function of time and
pharmacokinetic models are commonly used to describe the time varying proﬁles.
Time varying inhibition of the proliferation of replicating species is a natural
consequence of the time varying drug concentrations. The time varying aspect of
the inhibition combined with the dynamics of the circular/proliferative system
makes it difﬁcult to predict the eventual outcome without the help of PK–PD-
Disease simulation models. However, time varying inhibition of proliferative
systems can be handled by calculating the equivalent effective constant
concentration (ECC) [20]. ECCss is the constant plasma concentration that would
give rise to the same average inhibition of proliferation at steady state as the time
varying concentration. The ECCss is obtained by ﬁrst calculating the time varying
viral inhibition proﬁle;
Time Varying Inhibition INHss ¼
CSSðTADÞ
IC50 þ CSSðTADÞ
ð14Þ
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AUC0 x under INH curve
s
ð15Þ
INHavgss ¼
ECC
IC50 þ ECC
ð16Þ
ECCss ¼
IC50   INHavgss
1   INHavgss
ð17Þ
where Css(TAD) is the steady state concentration at a given time after dose (TAD).
The ECCss is the calculated concentration that gives rise to INHavgss across the
dosing interval.
Attributes of the link between pharmacokinetics and circular/proliferative and
pharmacodynamic disease models
1. To be equally efﬁcacious at steady state (i.e. same proliferation rate), two
treatments (e.g. QD vs. BID) should give rise to the same average R0 in the
presence of the inhibitor, at steady state (i.e. R0-INHss) and therefore should
have the same ECC.
2. At R0-INHss equal to 1, ECC is equal to RMIC.
Methods
Simulations
Parameter values of the simple circular/proliferative dynamic model used in the
simulations are presented in Table 1.
Parameters of the more complex viral dynamic model used in the simulations
were obtained from the literature [17, 20] and slightly adapted for didactic purposes
(e.g. R0 and IC50). The values of the relevant model parameters are given in Table 2.
Various effect (e.g. viral load) time proﬁles, under different conditions, were
simulated by implementing the simple and viral dynamic models with the parameter
estimates given in Tables 1 and 2 in Trial Simulator TS2 version 2.1.2. (Pharsight,
Table 1 Parameter values used for the simulations with the simple circular/proliferative system model
Parameter Parameter description Value CV
a (%)
km Production rate (h
-1) 0.5
kd Death rate (h
-1) 0.1
R0 Basic reproductive ratio 5 30
IC50 Plasma concentration of inhibitor giving 50% inhibition (ng/ml) 10 30
RMIC Reproduction minimum inhibitory concentration (ng/ml) 40
a Coefﬁcient of variation
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123Mountain View, CA, USA). The results of the simulations were analysed in S-PLUS
6.1 (Insightful Corporation, Seattle, WA, USA).
Viral load-time proﬁles in a typical subject (i.e. using model mean parameter
values) were also simulated for various constant levels of inhibition (INHavg of 0,
0.1, 0.3, 0.5, 0.6, 0.7, 0.75, 0.8, 0.85 and 0.9) starting at day 0 and lasting for a
period of 10,000 days.
Simulations were also performed to evaluate the interaction between dosing
regime, i.e. QD or BID dosing, and elimination rate on viral eradication (causing
R0-INH to be below 1). Simulations were performed for the steady state condition.
Plasma concentrations were simulated for a one compartment model [21] where
bioavailability was complete (F = 1), Ka = 1h
-1, V = 70 l, and where
Ke = 0.05, 0.1, 0.15 and 0.2 h
-1, giving rise to terminal half lives of 13.9, 6.93,
Table 2 Parameter values used for the simulations with the viral dynamic model
Parameter Parameter description Mean
R0 Reproductive ratio before virus infection and treatment 5.0
b Uninfected cell activation rate (day
-1) 1.0
d2 Actively infected cell death rate (day
-1) 0.693
IC50 IC50 after in vitro to in vivo scale factor (ng/ml) 10.0
d1 Uninfected cell death rate (day
-1) 0.0060
f1 Fraction of infected cells actively versus latently infected 0.96
d3 Latently infected cell death rate (day
-1) 0.0132
a Rate of conversion from latently to actively infected (day
-1) 0.0370
p/c Ratio of birth to death rate of virus 35.4
Table 3 PK/PD parameters used in the simulations shown in Fig. 6 together with the corresponding total
daily dose and PK metrics that lead to the same viral load outcome (middle graphs) for both QD and BID
regimes
Schedule Parameter description QD BID
Daily dose (mg) Daily dose 19.6 11.5
Ka (h
-1) First order rate constant for absorption 1 1
Ke (h
-1) First order rate constant for elimination 0.15 0.15
V (l) Volume of distribution 70 70
IC50 (ng/ml) Concentration that results in 50% inhibition 10 10
R0 Basic reproductive ratio 5 5
R0-INHss_avg R0 in the presence of the inhibitor, at steady state 1.00 1.00
Cminss (ng/ml) Minimum concentration at steady state 9.3 19.2
Cmaxss (ng/ml) Maximum concentration at steady state 207 72.8
AUC24hss (ng h/ml) Area under the curve, 0 to 24 h, at steady state 1,866 1,096
Cavgss (ng/ml) Average concentration at steady state 77.8 45.7
ECCss (ng/ml) Effective constant concentration at steady state 40.0 40.0
The dosing regimes were chosen to give an R0-INHss_avg of 1. It can then be seen that all other parameters
are different except ECCss (and which now equals RMIC)
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1234.62 and 3.47 h, respectively (Table 3). Data were simulated after a range of total
daily doses (1–40 mg), given once or twice daily. In conjunction with the
pharmacokinetic parameter values, parameter values of the simple circular/
proliferative model (Table 1) and the viral kinetic model (Table 2) were used
when deriving the inhibition (INH) and R0-INH. In these simulations, several metrics
were calculated at steady state (ss) for a dosing interval: Cmaxss, Cminss, area under
the concentration–time curve (AUCss), area under the inhibition-time curve
(AUCINHss), area under the R0–time curve AUCR0ss), average concentration
(Css_avg = AUCss/s), average inhibition (INHss_avg = AUCINHss/s), average
R0-INH (R0 INHss avg ¼ AUCR0ss/s) and ECCss. These metrics were then compared
with the observed viral outcome.
Lastly, simulations were performed using parameters of Table 2 where the
probability of virological success (eradication of virus) was simulated as a function
of drug concentration (ECCss). R0 and IC50 were sampled for 1,000 individuals
assuming an inter-subject variability of 30% CV in the population (Table 1).
Corresponding individual RMIC were calculated using Eq. 7. Success probability
was estimated for a given ECC by calculating the cumulative density of subjects
with RMIC below the ECC divided by 1,000. To simulate the trial outcome, 1,000
ECC values between 1 and 1,000 ng/ml were sampled (with replacement) and
assigned to the 1,000 subjects. When the ECC was higher than the RMIC, the
patient was considered to have a treatment success (and assigned a value of 1).
When ECC was lower the patients was considered to have a treatment failure (and
assigned a value of 0). Simulated success as a function of the ECC was analyzed by
logistic regression.
Results
Circular/proliferative viral dynamic model
Viral load-time proﬁles in a typical subject (i.e. using model mean parameter
values) simulated for various constant levels of inhibition starting at day 0 and
lasting for a period of 10,000 days, are presented in Fig. 3. The results show that at
inhibitor concentrations higher than the RMIC (e.g. IC [40 ng/ml) the viral load
decreases rapidly and does not rebound, whereas at lower levels (e.g. IC\40 ng/ml)
the viral load decreases rapidly initially, but then returns to a new steady state level
close to the baseline value. It can also be seen that viral load rebounds faster at
lower inhibitor concentration levels (e.g. IC = 15 vs. IC = 35 ng/ml).
The simulations presented in Fig. 3 have been summarized in Fig. 4. Here the
viral load-time proﬁles are now depicted for the ﬁrst 10 days of treatment and at
equilibrium (e.g. day 10,000) for the different INHavg values indicated. These results
highlight that the initial drop of the viral load (e.g. at day 10) is not particularly
indicative/predictive of viral load at equilibrium. It is only when the inhibition
reaches a critical high INHavg value (break point) that the system goes to extinction.
At INHavg values (slightly) lower than the break point, the virus (and the system)
adjusts to the constant inhibition and, after an initial drop, viral load rebounds to
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123equilibrate at a new level towards the baseline before treatment. Therefore it is
almost impossible to identify the INHavg break point value using viral load
information at day 10 only.
In Fig. 5 the predicted viral loads at equilibrium shown in Fig. 4 have been
plotted against the ECC for the various regimens that give rise to the INHavg values
used in Fig. 4. The resulting relationship is linear. Extrapolation of the relationship
shown in Fig. 5 shows that, for this hypothetical example, if the ECC is maintained
above 40 ng/ml then viral eradication should ensue in the long term.
Inﬂuence of dosing regime/elimination half life
Whatever the dose, dosage schedule or PK parameters, scenarios that have the same
average R0-INHss_avg (or same ECCss) in the presence of inhibitor lead to the same
outcome. This is illustrated in Fig. 6 which shows that when the R0-INH_avg is just
higher than 1 (i.e. ECC\RMIC) in both QD and BID dosage regimes the viral load
rebounds after an initial drop whereas when the R0-INH_avg is just lower than 1 (i.e.
ECC[RMIC) the viral load continuously decreases. Interestingly, in the example
presented in Fig. 6 the daily doses that were necessary to reach the same average R0
(e.g. average R0-INHss_avg = 1) were signiﬁcantly different between the QD (e.g.
19.6 mg) and BID (e.g. 2 9 5.75 = 11.50 mg) dosage regimes (Table 3). In
addition, as illustrated in Table 3, the same viral load outcome in both QD and BID
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Fig. 3 Simulatedviralload–timeproﬁlesinatypicalsubjectexposedtovariousconstantlong-terminhibitor
concentrations (IC) corresponding to constant inhibition (INH) fractions (R0 = 5, IC50 = 10 ng/ml,
RMIC = 40 ng/ml, ‘breakout’ inhibition = 0.8)
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123treatments was not associated with the same Cmaxss, Cminss, AUC24hss or Cavgss.
However, as is expected from the theory, the same ECCss was observed and
corresponds to the calculated RMIC. Identical observations were made with the
simple circular/proliferative model (not shown).
The inﬂuence of dosing regime and half life is depicted further in Fig. 7. The
solid lines indicate the R0-INHss at the total daily dose, given QD. The dashed lines,
in the same colour for a given elimination rate, represent the R0-INHss when the total
daily dose was given as a BID regime. The solid horizontal black line at an R0-INHss
of 1 is the cut off point below which a particular dosing regime/elimination rate
would be predicted to result in viral eradication. Consideration of the solid and
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123dashed blue lines shows that a total single daily dose of just under 20 mg is
equivalent to a total daily dose of around 12 mg when given as 6 mg BID, in terms
of when R0-INH equals 1. Figure 7 also indicates that to have the same viral load
effect (same average R0-INHss), compounds with short half-lives require higher daily
doses when given QD than when given BID, whereas compounds with long half-
lives would require the same total daily dose. Figure 7 also conﬁrms that whatever
the dose, dosage schedule or PK parameters, scenarios that have the same ECC have
the same R0-INHss and therefore are expected to lead to the same outcome.
Insights into long term exposure response
As has already been stated, the RMIC is a joint distribution of R0 and IC50 in the
population. Knowing the distribution of the RMIC in the population and the
individual subject’s inhibitor concentration, then the chance/probability of success
can be estimated for each individual. These results are presented in Fig. 8. Building
on this further, the probability curve of success as a function of the inhibitor
concentration (ECC) (Fig. 9, bottom left graph) can be constructed if we know the
RMIC distribution in the population (Fig. 9, top graph) or the RMIC distribution in
the population can be derived if we know the success rate as a function of the
concentration (Fig. 9 bottom right hand graph). This type of approach was applied
to maraviroc, an anti-HIV drug of the entry inhibitor class, and the outcome is
presented in Fig. 10. Inspection of Fig. 10 shows that the probability of virological
failure based on the RMIC distribution estimated in the Phase IIa studies (i.e. short
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123term monotherapy) corresponded well with the probability of failure (deﬁned as a
viral load higher than 50 copies/ml) as a function of the ECC estimated in Phase IIb/
III studies in treatment experienced HIV positive patients receiving maraviroc on
top of an optimized background therapy.
Discussion
Disease progression modelling in combination with modelling the inﬂuence of drug
action on the parameters of the disease progression model can provide useful
information about the time course and outcome of pharmacological intervention on
the disease. The obvious ultimate goal is to best use new/existing pharmacological
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123agents for the beneﬁt of the patient. The basic principles of circular/proliferative
models for both a simple example where the organism does not interact with the
host at a cellular level, and, a more complex viral example where the organism
needs to interact intimately with the host cell to reproduce, have been presented.
The circular/proliferative viral dynamic model is based on the prey and predator
principle introduced by Lotka/Volterra [12, 13] almost one hundred years ago and
adapted for viral dynamics by Nowak and Bonhoeffer much more recently [14–17].
This viral dynamic model describes the interaction between the virus and the target
cells by means of differential equations and has been used to predict individual viral
load-time proﬁles after short as well as long term treatment [22].
The R0 concept that is central to the circular/proliferative systems described is
not new. Indeed, it has long a familiar concept in the epidemiological world where it
is used to gauge the risk of spread of infection with a pathogen and compare that to
other more well known pathogens [18]. The combination of R0 with PK/PD models
is rather new and has been discussed by several authors [23–26]. The combination
leads to principles speciﬁc to circular/proliferative systems such as the somewhat
unexpected linear concentration/effect relationship (on a linear axis) presented in
Fig. 5.
In the presence of a drug that inhibits the growth of the system the R0 in
combination with RMIC, gives an indication of how much drug will be needed to
cause the system to be eradicated in the long term. In case of inhibition that can be
described by an inhibitory Emax model acting on one of the circular aspects of the
system, the relationship between R0 and RMIC (Eq. 7) is simple and is useful at a
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Fig. 8 Histograms (blue bars) of the simulated distribution of RMIC in a population with different
individual IC values superimposed (vertical red lines). The particular individual IC values (25, 50, 75 and
100 ng/ml) have been used to calculate the associated probability of success of viral suppression (area on
the left hand side of the red bar divided by the total area)
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123high level in understanding what concentration/dose of drug is needed in order to
eradicate the system. This relationship shows that the critical concentration that
switches the system from growth to extinction not only depends on the potency of
the drug (i.e. IC50), but also on the capacity of the system to grow (i.e. R0); the
higher the capacity for growth, the higher the critical concentration needed to
eradicate the system. This is of particular importance for in vitro in vivo
extrapolation of efﬁcacious concentrations. If in vitro and in vivo systems have
different R0, then the RMIC will also be different in vitro and in vivo. Equation 7
can be used to correct for this difference. In terms of clinical study design short term
studies are (reasonably) required early on in the development of new compounds;
the efﬁcacy and safety information thus obtained is used to support/design the
performance of more long term studies. There are many examples in the literature
for viral infections in short term studies where outcome, in terms of viral load drop,
is said to predict long term clinical outcome [27–31]. The present work
demonstrates that the fall in viral load from short term studies alone cannot
reliably predict long term clinical outcome. What can be gained from such studies is
an estimate of IC50 for the drug under evaluation. Also if the study design is
extended so that a follow up period after treatment cessation has been included and
viral load re-growth is monitored, then applying models such as those described
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123herein can provide information about R0 [22] for the patient population under study.
Under such conditions, with quantitative information about both the IC50 of the
compound in question and the R0 for the particular virus in the population, the
RMIC can be calculated (Eq. 7) which gives an indication about the target exposure
that needs to be reached to have a given chance/probability of success in the long
term.
Figure 3 shows that the time of failure of an inhibitory drug treatment is a
function of the [inhibitory drug]/RMIC ratio; for failure (when the ratio is below 1),
the smaller the ratio, the sooner the failure will occur. Therefore the time of failure
(in the absence of resistance) also provides a quantitative indication of how far the
current exposure is from the critical RMIC and could be the basis for a therapeutic
decision to either increase the dose of the inhibitor or switch to another inhibitor.
The incorporation of the pharmacokinetics into the combination of circular/
proliferative models with disease models allows an understanding to be developed
around what the outcome might be if dosing regimes are changed, and what measure
of exposure best drives the circular/proliferative models and disease model system.
It is frequently stated that efﬁcacy is probably more related to AUC and side effects
are probably driven by Cmax. In the therapeutic area of bacteriology this is taken
further and effect is usually attributed to either AUC/MIC (concentration
dependent) or the length of time that the concentration is above the MIC (time
dependent or ‘concentration independent’), for different classes of drug and
pathogens [32]. Karlsson et al. [33] developed a general time dissociated model for
paclitaxel myelosuppression and showed that the commonly used terms of
concentration dependent or concentration independent drug action are both speciﬁc
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123cases of a more general model. In the present treatise different pharmacokinetic
parameters have been explored to see which best relate to eventual outcome. Of
these, R0 (averaged over the dosing interval, at steady state, in the presence of the
inhibitor) or ECC (at steady state in our simulations) in combination with RMIC
were the measures that best predicted outcome for two different dosing regimes
(Table 3). In the simulated examples, an inhibitory Emax model acting on one of
the circular aspects of the systems has been used. It can be shown that, whatever the
inhibitory function (e.g. linear, log-linear, exponential, sigmoid Emax, operational
antagonism) used, if two treatments have the same average R0 in the presence of the
inhibitor, at steady state (i.e. R0-INHss), then they will be equally efﬁcacious, thus
treatment success depends essentially on the pharmacokinetic characteristics of the
drug and the dosing schedule. This approach allows calculation of equivalent
effective doses for different compounds with different pharmacokinetics (e.g.
volume or/and clearance) or/and pharmacodynamic (e.g. IC50) potencies or for
different dosage schedules (e.g. QD vs. BID). However, with respect to the latter
aspect, it must be kept in mind that the transient variations of the system during a
dose interval (i.e. maximum and minimum effects) should not induce unacceptable,
non-linear or irreversible outcomes.
Inspection of Fig. 9 shows that if the distribution of the RMIC in the population
is known then the relationship between the probability of treatment success as a
function of inhibitory drug exposure (using ECC) can be obtained. On the other
hand, if the distribution of the RMIC in the population is not known (study design
thus far has not been sufﬁcient to allow characterisation of the RMIC distribution)
then logistic regression analysis of a study where a binary outcome has been
measured (clinical success/failure), plotted as a function of the inhibitory drug
concentration (ECC) will allow the derivation of the RMIC distribution in the
population. In this way logistic regression analysis which is usually viewed as a
purely descriptive analysis can be used to gain mechanistic information about the
biological system. Data presented in Fig. 10 show that both approaches led to the
same information with regard to the probability of failure (or success) as a function
of the inhibitory drug exposure and were conﬁrmatory of each other.
Within the ﬁeld of HIV treatment, modelling of disease progression and the
effects of therapy has been relatively limited thus far. Some examples are Huang
et al. [24] and Wu et al. [26] who both used a model similar to the complex viral
model described herein and linked it to pharmacokinetic parameters (such as Cmax,
AUC and Ctrough) and adherence in order to predict virological response. Labbe ´ and
Verotta [34] also used a system of differential equations to describe the dynamics of
viral load together with adherence and took the approach one step further by
demonstrating that increased adherence was associated with a lower R0. However,
they did not complete the circle by using the model to deﬁne if a treatment would be
successful or not, in the long term (other authors have looked at adherence in the
long term [23, 35]). A thorough review of the disease modelling work done thus far
in the HIV ﬁeld is not a goal of this work; nor is it even required from the
perspective of illustrating the basic PK/PD principles of circular/proliferative
systems. The reader is referred elsewhere for such a summary [36].
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123The circular/proliferative systems approach that has been presented here only
presents the theoretical aspects of a dose–concentration–effect relationship in the
absence of emerging resistance due to mutation and has also ignored the
complications of using combination therapy and the role of the immune response.
The reality is more complex and most of what has been theoretically described
could be hidden in practice by resistance phenomena. However, the probability of
the emergence of resistant mutations is a function of the average R0-INH and could
be incorporated into the model as well as extending the model to take account of
multiple treatment agents on R0-INH. The subject of resistance has been addressed by
other authors [23, 37, 38] and is not covered in the present paper.
Other assumptions that have been made include that the HIV model presented
has been simpliﬁed from the full model which included both defectively and
persistently infected cells. The latter are the reason why viral eradication cannot be
obtained despite a sustained R0 lower than 1 in the presence of inhibitor. This is in
contrast to what is observed for bacterial or HCV infections where, at a certain time
in treatment, the numbers of bacteria or virus and infected cells can be brought
below the critical value required to re-generate an infection and so the infection can
be eradicated.
In conclusion, the basic PK/PD principles of circular/proliferative systems have
been presented by means of a simple model and a more complex viral dynamic
model. A fundamental parameter of the circular/proliferative system is the R0. The
combination of R0 with PK/PD leads onto the model parameter RMIC which is the
Reproduction Minimum Inhibitory Concentration. The importance of deﬁning the
R0 and the RMIC for the particular infected system and inhibitor under
consideration has been illustrated, with respect to identifying the dose and dosing
schedule that can be successful or not in the long term.
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